Clinical trial · Observational
Evaluation of CMV/EBV-CMI in Haploid HSCT
Evaluation of Cytomegalovirus and Epstein-Barr Virus Specific Immune Reformulation in Prophylaxis for Cytomegalovirus in Haploid Hematopoietic Stem Cell Transplantation
NCT06554197CI-TRIAL-00079856unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cytomegalovirus Infections | — | UNRESOLVED | — |
| Epstein-Barr Virus Infections | — | UNRESOLVED | — |
| Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CMV/EBV-CMI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- CMV-CMI
- timeFrame
- 6 months after transplantation
- description
- CMV specific immune reconstitution from pre-HSCT to 180 days after HSCT
- measure
- EBV-CMI
- timeFrame
- 6 months after transplantation
- description
- EBV specific immune reconstitution from pre-HSCT to 180 days after HSCT
Secondary outcomes (7)
- measure
- Cumulative incidence of CMV reactivation
- timeFrame
- 1 years after transplantation
- description
- The cumulative incidences of CMV reactivation after transplantation.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. All patients were diagnosed with hemopathy. 2. All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus. 3. All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study. Exclusion Criteria: Patients with any conditions not suitable for the trial (investigators' decision).
References
Publications (0)
Data not yet available
No reference posted for this study.